MARKET

CRIS

CRIS

Curis
NASDAQ
0.5124
+0.0124
+2.48%
Opening 13:02 05/14 EDT
OPEN
0.5001
PREV CLOSE
0.5000
HIGH
0.5168
LOW
0.5001
VOLUME
70.77K
TURNOVER
--
52 WEEK HIGH
3.130
52 WEEK LOW
0.4901
MARKET CAP
20.49M
P/E (TTM)
-0.4284
1D
5D
1M
3M
1Y
5Y
1D
Curis Inc. Earnings Call Highlights Clinical Momentum
TipRanks · 19h ago
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/13/26?
TipRanks · 1d ago
Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSL
TipRanks · 1d ago
Curis Buy Rating Reiterated as Analyst Highlights Dual-Blockade Progress and Clinical Catalysts; $17 Price Target Maintained
TipRanks · 1d ago
Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27
Seeking Alpha · 1d ago
Curis reports Q1 EPS ($1.25), consensus (29c)
TipRanks · 1d ago
Curis sees cash and proceeds enough for operations into second half of FY27
TipRanks · 1d ago
Curis Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 1d ago
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.